Lexicon Pharma - LXRX Quarterly EPS earnings growth

Lexicon Corp - graphic logo of issuer LXRX

The development of metabolic drugs is constrained by strict regulatory oversight and costly testing. Lexicon Pharmaceuticals (LXRX) maintains stability through Inpefa sales and insurance reimbursements, which generate positive cash flow. Strong patent protection is offset by high marketing expenses. The quarterly EPS growth rate illustrates the market reaction to financial reports, with the metric currently standing at 10.30, helping investors avoid overpaying for the asset.

Lexicon Pharmaceuticals, Inc. (LXRX) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Lexicon Pharmaceuticals (LXRX)

- share price and consensus valuation forecast:
Analysis of all company metrics:Lexicon Pharmaceuticals
Manufactured product of Lexicon Corp

The indicator is calculated as the percentage change in net earnings per share between the current and previous quarter. This metric objectively measures the pace of profit generation, eliminating emotional factors when assessing the asset. For Lexicon Pharmaceuticals (LXRX), EPS dynamics reflect the efficiency of its expansion into the metabolic drug market. Profit growth correlates directly with the implementation of new cardioprotectors. Investors should utilize quarterly EPS growth tracking to monitor liquidity and return on equity.

Competitors of Lexicon Pharmaceuticals (LXRX)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS